logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11547703 B1

PDFFull Text
Date of Patent:
Jan. 10, 2023

Filed:

Feb. 26, 2018

Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof

Applicant:

Impact Therapeutics (Shanghai), Inc, Shanghai, CN;

Inventors:

Suixiong Cai, Shanghai, CN;

Ye Edward Tian, Shanghai, CN;

Xiaozhu Wang, Jiangsu, CN;

Assignee:

IMPACT THERAPEUTICS (SHANGHAI), INC, Shanghai, CN;

Attorney:

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Primary Examiner:

Amy C Bonaparte

Int. Cl.
CPC ...
A61K 31/444 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/167 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/436 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 31/475 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5025 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/635 (2006.01); A61K 31/675 (2006.01); A61K 38/31 (2006.01); A61K 39/395 (2006.01); C07D 471/04 (2006.01); C07D 471/14 (2006.01); C07D 487/04 (2006.01); C07D 487/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/167 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 31/475 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/635 (2013.01); A61K 31/675 (2013.01); A61K 33/243 (2019.01); A61K 38/31 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01); C07D 471/14 (2013.01); C07D 487/04 (2013.01); C07D 487/14 (2013.01);
Abstract

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A-A, B-B, D-Dand R-Rare defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

Find Patent Forward Citations

Loading…